^
Association details:
| Biomarker: | LRP1B mutation + TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of LRP1B mutants with immune biomarkers in Chinese non-small cell lung cancer patients.
Published date:
05/19/2021
Excerpt:
...208 (20%) of the 1056 Chinese patients and 385 (37%) of the 1053 Western patients had at least one mutation of LRP1B genes (LRP1B mutant group)....Patients with LRP1B mutation were associated with prolonged survival in Western immunotherapy cohort....Both in Chinese and Western cohorts, the higher TMB in LRP1B mutant patients suggested potential efficacy from immunotherapy of LRP1B mutant group.
DOI:
10.1200/JCO.2021.39.15_suppl.e21060
